

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date. 21/07/2020

To

Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Ref: BSE Security Code 540694

Sub: Audited Financial Results For the Half Year and Financial Year ended 31st March, 2020

Dear Sir/ Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith:

1. Audited Financial Results of the Company for the half year and financial year ended March 31, 2020 as approved in the Board of Directors Meeting held today, along with the Auditor's Report thereon received from M/s Ajay K. Khanna & Co., Statutory Auditors of the Company.
2. Declaration pursuant to Reg. 33(3)(d) of Listing Regulations.

Kindly take this information on your record.

Thanking You,

Yours Faithfully

For **ANG Lifesciences India Limited**

Rajesh Gupta
(DIN: 01423407)
Managing Director

Factory:
Village: Kishanpura,
Nalagarh Road,
Tehsil: Baddi,
Distt.: Solan,
HP-174101

Regd. Office : SCO-113,
DARBARA COMPLEX,
First Floor, B-BLOCK,
Ranjit Avenue, Amritsar.
Ph. 0183-5133455, 5133458
E mail :- operations@anglifesciences.com
website : www.anglifesciences.com

ANG Life Sciences India Ltd.

CIN : L24230PB2006PLC030341

Registered Office : 113, First Floor, Darbara Complex,

Ranjit Avenue, Amritsar

Email ID : cs@anglifesciences.com, Website : www.anglifesciences.com

AUDITED STANDALONE FINANCIAL RESULTS FOR HALF YEAR ENDED AND THE YEAR ENDED 31st MARCH, 2020

(In Lacs)

Particulars	Half Year Ended			For the year ended	Previous Year Ended
	31.03.2020	30.09.2019	31.03.2019	31.03.2020	31.03.2019
	Audited	Unaudited	Audited	Audited	Audited
I. Revenue from operations	6820.13	5862.99	6736.31	12683.12	12169.98
II. Other income	29.40	12.57	14.94	41.97	23.27
III. Total Revenue (I + II)	6849.53	5875.56	6751.25	12725.09	12193.25
IV. Expenses:					
(a) Cost of materials consumed	4683.61	4272.07	4840.53	8955.68	8888.65
(b) Changes in Inventories	-115.67	56.90	-93.89	-58.77	-104.55
(c) Employee benefits expense	525.93	267.70	323.44	793.63	639.13
(d) Finance costs	137.88	148.86	132.76	286.74	234.27
(e) Depreciation and amortization expense	68.04	54.83	56.88	122.87	112.37
(f) Other expenses	1105.75	678.57	1017.99	1784.32	1612.51
Total expenses	6405.54	5478.93	6277.71	11884.47	11382.38
V. Profit before exceptional and extraordinary items and tax (III-IV)	443.99	396.63	473.54	840.62	810.87
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00
VII. Profit before extraordinary items and tax (V - VI)	443.99	396.63	473.54	840.62	810.87
VIII. Extraordinary Items	0.00	0.00	0.00	0.00	0.00
IX. Profit before tax (VII- VIII)	443.99	396.63	473.54	840.62	810.87
X Tax expense:					
(1) Current tax	127.65	112.35	170.12	240.00	236.53
(2) Deferred tax	-8.82	-0.12	2.74	-8.94	2.74
(3) Mat Credit Entitlement	0.00	0.00	6.70	0.00	6.70
XI Profit (Loss) for the period from continuing operations (VII-VIII)	325.16	284.40	293.98	609.56	564.90
XII Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIII Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00



XV	Profit (Loss) for the period (XI + XIV)	325.16	284.40	293.98	609.56	564.90
XVI	Earnings per equity share:					
	(a) Basic & Diluted (Rs.)	6.27	5.49	5.67	11.76	10.90
	(b) Diluted (Rs.)	6.27	5.49	5.67	11.76	10.90

Notes :

- 1) The Audit Committee has reviewed these results and the Board of Directors have approved the above results at their meeting held on July 21, 2020.
- 2) As the Company's business activities falls with in a single segment, the disclosure requirement of the Accounting Standard AS(17) "Segment Reporting" as notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules 2014 are not applicable.
- 3) The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary to confirm the figures in the current period.
- 4) The Figures for the half year ended 31st March 2020 and corresponding half year i.e. half year ended 31.03.2019 are the balancing figures between the audited figures in respect of the full financial year.
- 5) As per MCA Notification dated 16.02.2015, companies whose shares are listed on SME exchange as referred in ChapterXB of SEBI(Issue of Capital Disclosure requirements) regulations 2009 are exempted compulsory requirements of adoption of IND-AS. As the company is covered under the exempted category, the company has not adopted IND -AS for preparation of Financials Results.
- 6) There were no Investors complaints pending as on 31.03.2020.
- 7) **Impact of Covid 19:** Covid 19 has resulted into restriction on the movement of goods and resources during March 23 to March 31, 2020 falling into the financial year under audit. Year End inventory could not be performed. However, inventory counts were observed subsequent to the year end and rolled back to year end.

For ANG Life Sciences India Limited



 (Managing Director)
 Rajesh Gupta
 (DIN : 01423407)

Date : 21.07.2020

Place : Amritsar

ANG Life Sciences India Ltd.
CIN : L24230PB2006PLC030341
Registered Office : 113, First Floor, Darbara Complex,
Ranjit Avenue, Amritsar
Email ID : cs@anglifesciences.com
Website : www.anglifesciences.com

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Amount in Lacs)

Sr. No.	Particulars	For the year ended	For the year ended
		31.03.2020	31.03.2019
I.	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) <u>Share capital</u>	518.33	518.33
	(b) <u>Reserves and surplus</u>	2937.22	2358.40
	Sub-total-Shareholders' Fund	3455.55	2876.73
2	Non-current liabilities		
	(a) <u>Long-term borrowings</u>	525.00	627.76
	(b) <u>Other Long-term liabilities</u>	286.21	290.08
	(c) <u>Deferred Tax Liabilities (Net)</u>	30.76	39.69
	(d) <u>Long-term Provisions</u>	20.31	15.06
	Sub-total-non Current Liabilities	862.27	972.60
3	Current liabilities		
	(a) <u>Short Term Borrowings</u>	1291.94	1241.45
	(b) <u>Trade Payables</u>		
	<u>Due to Micro, Small & Medium Enterprise</u>	443.06	161.49
	<u>Due to Others</u>	2135.90	2019.97
	(c) <u>Other current liabilities</u>	978.79	592.45
	(d) <u>Short-term provisions</u>	240.00	225.08
	Sub-total-Current Liabilities	5089.69	4240.44
	TOTAL EQUITY AND LIABILITIES	9407.51	8089.76
II.	ASSETS		
	Non-current assets		
1	(a) <u>Property, Plant and Equipment</u>		
	(i) <u>Tangible assets</u>	2093.73	2059.64
	(ii) <u>Intangible assets</u>	23.12	16.30
	(b) <u>Other non-current Investments</u>	2.00	2.00
	(c) <u>Deferred Tax Assets (Net)</u>	0.00	0.00
	(d) <u>Long-term loans and advances</u>	0.00	0.00
	(e) <u>Other non-current assets</u>	17.37	15.92
	Sub-total-non Current Assets	2136.22	2093.86
2	Current assets		
	(a) <u>Current Investments</u>	0.00	0.00
	(b) <u>Inventories</u>	1000.43	653.73
	(c) <u>Trade receivables</u>	4606.42	4174.87
	(d) <u>Cash and cash equivalents</u>	360.05	437.15
	(e) <u>Short-term loans and advances</u>	725.14	198.98
	(f) <u>Other Current Assets</u>	579.25	531.17
	Sub-total-Current Assets	7271.29	5995.90
	TOTAL ASSETS	9407.51	8089.76
	See accompanying notes forming part of the financial statements.		

For ANG Life Sciences India Limited

(Managing Director)

Rajesh Gupta

(DIN : 01423407)


Date : 21.07.2020

Place : Amritsar

ANG Life Sciences India Ltd.
R.O. 113, First Floor, Darbara Complex,
Ranjit Avenue, Amritsar

CASH FLOW STATEMENT FOR THE PERIOD ENDED 31ST MARCH 2020

Particulars	As at 31st March 2020	Year ended 31st March 2019
(A) CASH FLOW FROM OPERATING ACTIVITIES		
1 Net Profit/(loss) before extraordinary items and Tax	60956126	56489861
2 Adjustments for ;		
a) Depreciation and Amortisation	12287172	11237165
b) Finance Cost Expenses	28673974	23427409
c) Current Taxes	24000000	23652653
d) Deferred Taxes	-893876	274067
e) Preliminary Expenses	0	0
f) MAT Credit	0	0
Operating Profit before working capital Changes (1+2)	125023396	115081156
3 Adjustments for Working Capital Changes ;		
(i) (Increase)/decrease Operating Assets		
a) Trade Receivables	-43154932	-95984211
b) Short Term Loans and Advances	-52616372	-17994236
c) Other Current Assets	-4807514	0
(ii) Increase/(Decrease) in Operating Liabilities		
a) Trade Payables	39750226	-5006170
b) Short Term Provisions	2000000	12076111
c) Other Current Liabilities	38126630	2358825
d) Other Long Term Liability	-387178	14026171
e) Long Term Provisions	525420	1505786
f) Short Term Borrowings	5049085	60155238
(iii) (Increase)/Decrease in inventories	-34669740	12055366
Less : Income Tax Paid (Net)	74839022	98274035
	-24000000	-23652653
Net Cash from Operating Activities (A)	50839022	74621382
(B) CASH FLOW FROM INVESTING ACTIVITIES		
a) Purchase of Fixed Assets including Capital W.I.P.	-16421018	-8417868
b) Change in Non-Current Assets	-144802	700640
c) Change in Non-Current Investment		0
Net Cash from Investing Activities (B)	-16565820	-7717228



(C)	CASH FLOW FROM FINANCING ACTIVITIES		
a)	Interest paid	-28673974	-23427409
b)	Proceeds from Long Term Borrowings	17250000	4300000
c)	Repayment of Long Term Borrowings	-27526710	-18356303
d)	Proceeds from issue of Share Capital	0	0
e)	Proceeds from Share Premium	0	0
f)	Proceeds from sale of assets	0	0
g)	Decrease in Capital Reserve	-500000	-500000
	Net Cash from Financing Activities (C)	-39450684	-37983713
(D)	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	-5177482	28920441
(E)	Cash & Cash Equivalents at the beginning of the year	43714848	14794408
(F)	Cash & Cash Equivalents at the end of the year	38537366	43714848

Note : 1 Components of Cash & Cash Equivalents

Cash in hand

Balance with Schedule Banks

in Current Accounts

2. The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Accounting Standard-3 on Cash Flow Statement issued by the Institute of Chartered Accountants of India

3. The previous year's figures have been regrouped wherever necessary.

For ANG Life Sciences India Limited



(Managing Director)
Rajesh Gupta
(DIN : 01423407)

Date : 21.07.2020

Place : Amritsar



Independent Auditor's Report on Audited Standalone Half Yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**TO
THE BOARD OF DIRECTORS
OF ANG LIFESCIENCES INDIA LIMITED**

Report on the audit of the Standalone Financial Results

Opinion


We have audited the accompanying standalone Half yearly financial results of ANG Lifesciences India Limited (the company) for the half year ended 31st March, 2020 and the year to date results for the period from 01st April, 2019 to 31st March, 2020, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the half year ended 31st March, 2020 as well as the year to date results for the period from 01st April, 2019 to 31st March, 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Standalone Financial Results

These Half Yearly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.


- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Ajay K Khanna Co.
Chartered Accountants
Firm Reg. No.012303N



Bhupinder Singh
Partner
M.No.513899

UDIN: 20513899 AAAACC9614

Date: 21.07.2020
Place: Amritsar

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date. 21/07/2020

To

Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Ref: BSE Security Code 540694

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

In accordance with Reg. 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended by SEBI (Listing Obligation and Disclosure Requirements), Regulations 2016, it is hereby declared that M/s Ajay K. Khanna & Co., Chartered Accountants, Statutory Auditors of the Company have issued an Auditor's Report with unmodified opinion on the Standalone Audited Financial Results of the Company for the Half year and Financial Year ended March 31, 2020 as approved in the Board Meeting held on 21st July, 2020.

Kindly take the same on your record and acknowledge the receipt.

Thanking You,

Yours Faithfully

For **ANG Lifesciences India Limited**


Rajesh Gupta
(DIN: 01423407)
Managing Director

Factory:
Village: Kishanpura,
Nalagarh Road,
Tehsil: Baddi,
Distt.: Solan,
HP-174101

Regd. Office : SCO-113,
DARBARA COMPLEX,
First Floor, B-BLOCK,
Ranjit Avenue, Amritsar.
Ph. 0183-5133455, 5133458
E mail :- operations@anglifesciences.com
website : www.anglifesciences.com